Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (21399)	1/7/1999 4:53:00 AM
From: up3up4	Read Replies (2) \| Respond to of 120523

Jenna, I am still holding CMGI and VRSN. I think CMGI will be at 170-180 when split. VRSN might have strength to test its new high before expiration. I hold CMGI Jan 125 (bought at 110) and might exercise half of my position. What's your take on VRSN since we have a hugh reverse yesterday? up3up4

To: Jenna who wrote (21399)	1/7/1999 6:18:00 AM
From: kha vu	Read Replies (2) \| Respond to of 120523

WSJ: Heard On The Street 01/06 -- Monsato. MTC got FDA approval of Celebrex as pain killer for arthritis applications whereas MTC and investors have been expected this drug to be approved as nonsteroidal antiflammatory drugs,NSAIDs, to treat any type of pain. FDA also requires Celebrex to include gastrointestinal ulcer warnings to the label. The silver lining for MTC is the FDA approval made Celebrex the first in the new class of pain killer called Cox-2 inhibitors. Safety in this new class can rack up the sale to $1 billion range as of next year. But investors also learn that Merk, MRK, is expected to launch its Cox-2 inhibitor: Vioxx in about 2 to 3 months. FDA will approve MRK applications as a broader pain medication. Shares of MRK has been up since then.